Yanli Sun

Prof. Yanli Sun


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2017 in Journal of Bioscience and Bioengineering
Verified
Journal Article
Closed access
YSYanli Sun
Yanli Sun
YSYanhua Sun
Yanhua Sun
RZRonglan Zhao
Ronglan Zhao

6 January 2021 in Reproductive Sciences
Verified
Journal Article
Closed access
PDF file
XLXuening Li
Xuening Li
XLXiugui Li
Xiugui Li
YSYanhua Sun
Yanhua Sun
JHJie Han
Jie Han
HMHuagang Ma
Huagang Ma
YSYanli Sun
Yanli Sun

23 April 2018 in BMC Cancer
Verified
Journal Article
Open access
PDF file
LWLin Wang
Lin Wang
YSYanhua Sun
Yanhua Sun
YSYanli Sun
Yanli Sun
LMLingbin Meng
Lingbin Meng
XXXin Xu
Xin Xu
Leukemia is different from solid tumor by harboring genetic rearrangements that predict prognosis and guide treatment strategy. PML-RARA, RUNX1-RUNX1T1, and KMT2A-rearrangement are common genetic rearrangements that drive the development of acute myeloid leukemia (AML). By contrast, rare genetic rearrangements may also contribute to leukemogenesis but are less summarized. Here we reported rare fusion genes ZNF717-ZNF37A, ZNF273-DGKA, and ZDHHC2-TTTY15 in a 47-year-old AML-M4 patient with FLT3 internal tandem duplication (ITD) discovered by whole genome sequencing (WGS) using the patient’s healthy sibling as a sequencing control. This is, to our knowledge, the first case of AML with fusion gene ZNF717-ZNF37A, ZNF273-DGKA, and ZDHHC2-TTTY15.

4 December 2019 in Cellular and Molecular Bioengineering
Verified
Journal Article
Closed access
PDF file
YSYanli Sun
Yanli Sun
JLJiaqiu Li
Jiaqiu Li
YSYanhua Sun
Yanhua Sun
RZRonglan Zhao
Ronglan Zhao
LWLujuan Wang
Lujuan Wang
ZHZhenbo Hu
Zhenbo Hu

1 December 2025 in Frontiers in Immunology
Verified
Journal Article
Open access
YZYunke Zang
Yunke Zang
PZPeipei Zhou
Peipei Zhou
HDHaotian Dong
Haotian Dong
JWJingfei Wang
Jingfei Wang
RCRongxuan Cao
Rongxuan Cao
YSYanli Sun
Yanli Sun
Background: Multiple myeloma (MM), a malignancy of plasma cells in the bone marrow, urgently requires novel prognostic biomarkers. However, the prognostic significance of disulfidptosis-related genes and their association with treatment response in MM remain unclear. Methods: Transcriptomic data from MM samples were obtained from the Gene Expression Omnibus (GEO) database. A disulfidptosis-related prognostic model was constructed using LASSO-Cox regression analysis. The performance of the model was evaluated, and its clinical relevance to treatment response was subsequently assessed. Finally, the expression of the identified genes was validated by qRT-PCR and Western blotting. Results: Unsupervised cluster analysis identified a total of 121 differentially expressed genes. LASSO-Cox regression subsequently revealed a nine-gene prognostic signature comprising TPST2, HIF1A, KIF21B, MCPH1, MAST4, ANXA2, ALG14, PQLC3, and RANGAP1, which were used to establish and validate a robust risk stratification model. Partial validation demonstrated that ALG14, MCPH1, and PQLC3 were significantly downregulated, whereas TPST2 was markedly upregulated in MM cells. Conclusion: We established and validated a novel disulfidptosis-related prognostic model for MM, providing a potential biomarker for risk stratification and guidance for personalized therapeutic decisions.